Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.56 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.56 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10069523 | 0.94 | SLC2A1 (0.60) | SLC2A1KCNH2BCHETRPC3TRPC4 | |
| SCHEMBL178883 | 0.88 | BCHE (0.56) | SLC2A1KCNH2BCHETRPC3TRPC4 | |
| SCHEMBL178859 | 0.84 | MARS1 (0.51) | SLC2A1KCNH2 | |
| SCHEMBL19377809 | 0.82 | SLC2A1 (0.52) | SLC2A1KCNH2TP53SMN1; SMN2 | |
| SCHEMBL7104085 | 0.81 | SLC2A1 (0.66) | SLC2A1KCNH2BCHETRPC3TRPC4 | |
| SCHEMBL178919 | 0.80 | BCHE (0.51) | SLC2A1BCHETRPC3TRPC4TRPC5 | |
| SCHEMBL19377967 | 0.80 | RAB9A (0.64) | SLC2A1KCNH2MEN1GFERKMT2A | |
| SCHEMBL19378103 | 0.80 | SLC2A1 (0.44) | SLC2A1KCNH2RAB9A | |
| SCHEMBL178860 | 0.80 | MARS1 (0.47) | SLC2A1KCNH2 | |
| SCHEMBL19378081 | 0.78 | SLC2A1 (0.47) | SLC2A1KCNH2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | SLC2A1 4328/4885KCNH2 4860/4885BCHE 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.